Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval Kymriah® (tisagenlecleucel, formerly CTL019) receives European Commission Approval London, UK – 28 August 2018: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and...

Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford BioMedica, UK Cystic Fibrosis Gene Therapy Consortium, Boehringer Ingelheim and Imperial Innovations Form Partnership to Develop a Novel Gene Therapy Treatment for Cystic Fibrosis Oxford, UK –...

Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL Oxford BioMedica notes the sBLA submission to FDA for Kymriah(TM) in adult patients with r/r DLBCL Oxford, UK - 31 October 2017: Oxford BioMedica plc ("Oxford BioMedica" or "the Group")...

Oxford BioMedica plc: INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2017 OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2017 Oxford, UK - 17 August 2017: Oxford BioMedica plc ("OXB" or "the Group"; LSE: OXB), a leading gene and cell therapy...

Oxford BioMedica plc: Oxford BioMedica notes FDA Advisory Committee to review CTL019 Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, notes that the US Food and Drug Administration (FDA) has scheduled an Oncologic Drugs...